Targeting hypoxia in prostate cancer cells to increase treatment efficacy

Heather Nesbitt, niall byrne, Jenny Worthington, Stephanie McKeown, Declan McKenna

Research output: Contribution to journalArticle

Abstract

Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (
Original languageEnglish
Pages (from-to)209-210
JournalUlster Medical Journal
Volume84
Issue number3
Publication statusPublished - Oct 2015

    Fingerprint

Keywords

  • hypoxia
  • uHAP
  • OCT1002
  • bicalutamide
  • prostate cancer

Cite this